spacer
home > pmps > summer 2002 > the polish pharmaceutical industry - dynamic growth in a challenging legal environment
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Polish Pharmaceutical Industry - Dynamic Growth in a Challenging Legal Environment

The Polish pharmaceutical industry has undergone tremendous change during the 12 years of the economical and political transformation that has taken place since the fall of communism. The privatisation of the state-owned pharmaceutical producers and the fast-changing legal environment - particularly influenced by the ongoing accession negotiations with the European Union - form the landscape in which Polish and foreign producers currently operate.

Dynamic Growth

The Polish pharmaceutical market has been growing notably in the last few years. Sales of pharmaceuticals have risen from approximately US$500 million to US$2,500 million in 2001, with the year-on-year growth of sales recorded in 2001 equal to 17 per cent. Some forecasts envisage the pharmaceutical market equaling US$4,500 million in 2005.

The Polish market is characterised by fairly large unit sales per inhabitant (34 per inhabitant compared with 27 in Italy), but a relatively low value of each sale (approximately US$1.6 per sale compared with US$4.9 in France). Given the fact the typical Pole is fairly interested in his/her health, it can be expected that the value of each sale will rise in the future as the society becomes more affluent. There are approximately 200 pharmaceutical firms active in Poland, most of them relatively small, and overall employing around 20,000 people.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Wladyslaw Rzycki, Attorney at White & Case Wladyslaw Rzycki is a US and Polish Lawyer with experience in many tax, commercial and financial transactions in the US, including structuring and planning for multinationals, pharmaceutical companies, e-commerce companies and venture capital investment offshore.
Prior to joining White & Case in June 2001, Wladyslaw worked at the law firm Mayer, Brown & Platt in Chicago where his practice focused on mergers and acquisitions corporate taxation, international taxation and taxation of financial instruments.

spacer
Wladyslaw Rzycki
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccinesí dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement